RHEACELL
RHEACELL is a German biopharmaceutical company dedicated to developing innovative drugs, based on the platform technology around the ABCB5 gene family, especially on ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs) and has exclusive access to proprietary IP and know how. For its clinical trials, RHEACELL uses ABCB5+ MSCs produced by TICEBA, a company that is specialized in high-throughput, off-the-shelf GMP-manufactured ABCB5-positive mesenchymal stem cells (ABCB5+ MSCs). RHEACELL’s development program is supported by the Müller Holding and TICEBA, a specialist in stem cell manufacturing.
RHEACELL
Social Links:
Industry:
Biotechnology Pharmaceutical
Founded:
2003-01-01
Address:
Heide, Niedersachsen, Germany
Country:
Germany
Website Url:
http://www.rheacell.com
Total Employee:
101+
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible LetsEncrypt Apple Mobile Web Clips Icon Nginx Amazon Nginx 1.14 Amazon Frankfurt Region Nuxt.js Umbraco
Current Employees Featured
Official Site Inspections
http://www.rheacell.com
- Host name: 212.224.100.10
- IP address: 212.224.100.10
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "RHEACELL"
RHEACELL >< About Us
We are RHEACELL. A fully integrated biopharmaceutical company. First in class and best in class late-stage innovative stem cell therapies focusing on patients suffering from severe immune …See details»
RHEACELL GmbH & Co. KG - LinkedIn
With late-stage data available for CVU and an ongoing pivotal phase 3 trial for RDEB, RHEACELL is a leading biopharmaceutical company that is dedicated to developing innovative therapies for...See details»
EB-Trial - RHEACELL
Due to their immunomodulatory and anti-inflammatory properties, ABCB5+ mesenchymal stem cells (ABCB5+ MSCs) may represent a new, promising therapeutic approach to EB. The cell …See details»
RHEACELL - Crunchbase Company Profile & Funding
RHEACELL is a German biopharmaceutical company dedicated to developing innovative drugs, based on the platform technology around the ABCB5 gene family, especially on ABCB5 …See details»
Team - RHEACELL
Join forces with us delivering stem cell therapies to patients.See details»
Rheacell new clinical trial phase 3 - EB-Research
Rheacell new clinical trial phase 3. Due to their immunomodulatory and anti-inflammatory properties, ABCB5+ mesenchymal stem cells can offer a new innovative therapeutic approach …See details»
First Patient enrolled in Rheacell trial - EB-Research
The biopharmaceutical company Rheacell started its multicentre, worldwide phase 3 trial for the clinical testing of a stem cell therapy at the beginning of 2023. The first patient worldwide could …See details»
RHEACELL Company Profile 2024: Valuation, Funding & Investors
Operator of a biopharmaceutical company located in Heidelberg, Germany. The company develops stem cell-based drugs on a platform technology of ABCB5-positive bringing new …See details»
Innovative stem cell therapy for chronic wounds
Jul 28, 2022 · The Heidelberg company RHEACELL has developed a unique drug based on ABCB5-positive mesenchymal stem cells that helps reprogramme the relevant immune cells …See details»
RHEACELL announces FDA approval for Phase 3 study in …
Heidelberg, Germany, 24.09.2024 – RHEACELL today announced that the U.S. Food and Drug Administration (FDA) approved the companies blinded, multi-centric Phase-3 trial …See details»
Phase III Clinical Trial of ABCB5+ Stem Cells for RDEB
Mar 11, 2024 · RHEACELL is conducting a pivotal placebo-controlled phase III study to investigate the safety and efficacy of ABCB5+ Stem Cells administered intravenously to …See details»
Technology - RHEACELL
How does RHEACELL's ABCB5+ MSC approach work? The technology behind the clinic: unique, potent stem cell therapeutics from an expert, pioneering manufacturer. We use cutting-edge, …See details»
RHEACELL GmbH KG : Germany approves novel cell therapy …
Oct 6, 2021 · RHEACELL, a German biopharmaceutical company focused on clinical development of novel stem cell therapeutics, has been granted national approval under § 4b …See details»
RHEACELL - VentureRadar
Website: https://www.rheacell.com/ Develops biopharmaceutical drugs utilizing a stem cell biotech platform focused on addressing severe inflammation-driven diseases through ABCB5-positive …See details»
RHEACELL Company Insight - Pharma Technology Focus | Issue …
Oct 7, 2024 · RHEACELL, recognised as a leading integrative biopharmaceutical stem cell company, has been at the cutting edge of stem cell research for more than two decades. The …See details»
From Chronic to Curable? RHEACELL is Developing a Novel Cell …
Oct 19, 2021 · RHEACELL is a pioneer in stem-cell-based drug development. In addition to non-healing chronic venous wounds and non-healing diabetic foot wounds, its research focuses on …See details»
Clinical Research - RHEACELL
Clinical trials provide the crucial step for transforming science into therapy. Discover more about the clinical indications we are focusing on. RHEACELL clinical trial designs can be accessed …See details»
Take part: RHEACELL phase 3 clinical trial on systemic stem cell ...
Sep 19, 2024 · A new clinical trial from Rheacell is looking for 74 patients with severe forms of EB in various renowned study centers across Europe (EU and UK), Israel, Chile, Argentina, and …See details»
RHEACELL >< Newsroom
Mar 1, 2024 · RHEACELL has been granted national marketing authorization in Germany (§ 4b of the German Medicinal Products Act) for its’ cell therapy product AMESANAR®, produced by …See details»
Healing begins with research: Promising development program on …
Oct 14, 2024 · RHEACELL, headquartered in Heidelberg, Germany, has been at the cutting edge of stem cell research for more than two decades. Originally founded as TICEBA in 2003 by Dr. …See details»